CSIMarket
 
Medtronic Plc  (MDT)
 

Medtronic Plc Reports Strong Growth in Earnings and Revenue for Q3 2024

Global Healthcare Technology Leader Continues to Thrive Despite Sector Competition


Published Feb 28 2024 / Modified Feb 28 2024
CSIMarket Team / CSIMarket.com


Surgery_By_NathanGrohmann_(Own_work)_[[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_CommonsMedtronic Plc, a global leader in healthcare technology, recently reported its third-quarter results for 2024.
The company experienced a revenue growth of 4.685% to $8.09 billion compared to $7.73 billion in the same reporting season the previous year.
This represents a solid performance, although it falls short of the 8.27% top-line improvement reported by its contemporaries in the Medical Equipment & Supplies sector.

In terms of earnings per share (EPS), Medtronic Plc saw an increase of 7.61% to $0.99 from $0.92 in the prior year reporting season.
The company's bottom-line also showed improvement, with net earnings of $1,337.000 million in the third quarter of 2024, an 8.79% increase from $1,229.000 million reported in the same period a year ago.

One positive highlight from Medtronic Plc's third-quarter results is the improvement in profit margins.
The net margin rose to 16.53% in the third quarter of 2024, and the operating margin edged up to 18.33%. These improvements indicate that the company has been able to increase its profitability.

However, there are also some areas of concern.
The inventories have declined to $5,726.0 million compared to the previous quarter, but this marks an increase relative to the same period a year ago.
This suggests that the demand for Medtronic Plc's products may be slowing down.

Another signal of rising demand is the build-up in accounts receivable, which were valued at $5,968.0 million, higher than in the preceding quarter.
This indicates that customers are purchasing more from the company and may lead to increased revenue in the future.

Looking ahead, Medtronic Plc is expected to report its next financial results on February 29, 2024.
The company has also announced its participation in the 42nd annual J.P.
Morgan healthcare conference on January 8, 2024.
Medtronic's Chairman and CEO, Geoff Martha, will discuss the company's latest innovation, the Percept RC neurostimulator, which has recently received FDA approval.

The Percept RC neurostimulator is a breakthrough development in deep brain stimulation, as it is the first and only system with sensing, directionality, and advanced programming.
This innovative device has the ability to sense brain activity, provide targeted stimulation, and offer personalized programming.
It is expected to revolutionize the treatment of neurological disorders such as Parkinson's disease, epilepsy, and essential tremors.

Medtronic Plc's shares have seen a steady increase of 1.27% over the past year, bringing the year-to-date performance to 1.22%. The shares are currently trending higher and are just 8.9% off their 52-week high.

In conclusion, Medtronic Plc's third-quarter results for 2024 showed solid revenue growth and an improvement in earnings per share.
The company is also making strides in innovation, as evidenced by the FDA approval of its Percept RC neurostimulator.
However, there are some concerns regarding inventory levels and the impact on future demand.
Overall, Medtronic Plc continues to be a leading player in the healthcare technology industry with strong potential for future growth.



Medtronic Plc's Dividend Growth

Medtronic Plc's Income per Employee



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com